US FDA approves revisions to Triumeq (abacavir/dolutegravir/lamivudine) and Dovato (dolutegravir/lamivudine) prescribing information
The approved revisions include dosing in patients with creatinine clearance of 30-49 mL per min. These patients may experience a 1.6- to 3.3-fold higher lamivudine exposure and they should be monitored for haematological toxicities.
Source:
US Food and Drug Administration